OST-HER2 Shows Positive Data in Phase 1 Clinical Trial of HER2-expressing Solid Tumors

OST-HER2, a biologic therapeutic candidate being developed by OS Therapies, is a Listeriamonocytogenes (Lm-) vector-based off-the-shelf immunotherapeutic vaccine designed to prevent metastasis, delay recurrence, and increase overall survival in patients with osteosarcoma and other solid tumors. The proposed OST-HER2 mechanism of action is based on innate and adaptive immune stimulating responses activated by the Lm vector. This treatment generates T-cells that can eliminate or slow potential micrometastases that can grow into recurrent osteosarcoma and other solid tumors, including breast cancer.